Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Christel Larbouret

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8531-9552; OpenAlex author ID A5038051309. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
16
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 9

  1. ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment. Last author DOI 10.1038/s41416-024-02904-3↗
  2. Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances paclitaxel effect in pancreatic cancer mod… Last author DOI 10.1038/s41419-025-07747-1↗
  3. Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer. Co-author DOI 10.3389/fimmu.2023.1168444↗
  4. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. Last author DOI 10.1080/19420862.2021.1914883↗
  5. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Co-author DOI 10.1002/ijc.32273↗
  6. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical model… Last author DOI 10.1016/j.canlet.2018.06.023↗
  7. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "TH… Co-author DOI 10.18632/oncotarget.3473↗
  8. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. First author DOI 10.1038/onc.2013.487↗
  9. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Last author DOI 10.18632/oncotarget.2231↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pierre‐Emmanuel Colombo · 6 shared papers, 2014–2025 · strength 0.66
  2. André Pèlegrin · 7 shared papers, 2014–2023 · strength 0.50
  3. Marine Bruciamacchie · 3 shared papers, 2021–2025 · strength 0.48
  4. Thierry Chardès · 6 shared papers, 2014–2023 · strength 0.46
  5. Corinne Bousquet · 3 shared papers, 2018–2025 · strength 0.44
  6. Kévin Bigot · 2 shared papers, 2025 · strength 0.38
  7. Emilia Rabia · 2 shared papers, 2021–2023 · strength 0.24
  8. Christine Jean · 1 shared paper, 2025 · strength 0.19
  9. Bruno Robert · 4 shared papers, 2014–2018 · strength 0.18
  10. Charline Ogier · 2 shared papers, 2018–2019 · strength 0.14
  11. Gaëlle Thomas · 3 shared papers, 2014–2018 · strength 0.13
  12. Laura Bourillon · 1 shared paper, 2019 · strength 0.08
  13. Wilhem Leconet · 2 shared papers, 2014 · strength 0.07
  14. Marc Ychou · 1 shared paper, 2015 · strength 0.04
  15. Eric Assénat · 1 shared paper, 2015 · strength 0.04
  16. Fabienne Portales · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.